National Institutes of Health (NIH)

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

Only one NIDCD ECR Award (R21) application may be submitted by a PD/PI per due date. PD/PIs who successfully obtained an NIDCD Small Grant award are ineligible for an NIDCD ECR Award (R21).

Applicants may not submit an NIDCD R01, R15 or R21 application for the same review cycle that the NIDCD ECR Award application is submitted. In such cases, the NIDCD ECR Award R21 application will be withdrawn.

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

Only one NIDCD ECR Award (R21) application may be submitted by a PD/PI per due date. PD/PIs who successfully obtained an NIDCD Small Grant award are ineligible for an NIDCD ECR Award (R21).

Applicants may not submit an NIDCD R01, R15 or R21 application for the same review cycle that the NIDCD ECR Award application is submitted. In such cases, the NIDCD ECR Award R21 application will be withdrawn.

This Funding Opportunity Announcement is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications of genomics.

The PD/PI must be an NIH defined Early Stage Investigator, and this eligibility must be included in the NIH Commons record prior to the review of the application.

In addition, the PD/PI must be an independent researcher with a faculty appointment that is tenure track or equivalent (generally at the level of Assistant Professor or Research Assistant Professor), and have dedicated, independent laboratory space or access to the research resources which will allow them to conduct the research proposed in the grant application as the lead PD/PI

The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians.The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers.

The supplement is intended to allow candidates to expand their research experience to help them transition beyond their clinical training to the next stage of their research careers as physician-scientists.

Administrative supplements must support work within the scope of a currently funded basic, behavioral, and/or clinical DDEMD research project. PIs of projects focused on type 1 diabetes are highly encouraged to apply given the limited numbers of new MD researchers entering this area. All applicants are strongly encouraged to discuss potential requests with the NIDDK DDEMD program director of the award for which they wish to submit a supplement application. See https://www.niddk.nih.gov/about-niddk/staff-directory/by-office/division-diabetes-endocrinology-metabolic-diseases for DDEMD program director contact information.

This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups (NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply.

This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator­ initiated Research Project Grant (R01) or equivalent application.

Only New Investigators who fit the criteria in this section are eligible to apply to this FOA.

New Investigators whose proposed research addresses topics of relevance to the NIDCR mission are eligible and encouraged to apply. A New Investigator is one who has not previously competed successfully for substantial, independent R01 or R01-equivalent funding from NIH. When Multiple PDs/PIs are proposed, all PDs/PIs must meet the definition of New Investigator and the eligibility criteria as defined below. Current or past recipients of the NIDCR Small Grant for New Investigators (R03) grant are eligible to apply for a second NIDCR Small Grant for New Investigators (R03), provided they are still New Investigators. New Investigator status should be valid at the time of award.

Specifically, NIDCR is excluding from consideration individuals who have received:

NIH Exploratory/Developmental Research Grant (R21) support from any NIH Institute or Center, or
More than one Small Grant for New Investigators (R03) funded by NIDCR. Any PD/PI who has already received funding for two NIDCR Small Grants for New Investigators (R03) is not eligible.
Investigators who have questions about eligibility should contact the Scientific/Research Contact listed in Section VII. Agency Contacts.

The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.

Eligible candidates will identify with one of the two categories below:

1. New Investigator (NI)

For the purpose of this NOFO, an investigator is considered a New Investigator (NI; https://grants.nih.gov/policy/early-investigators/index.htm) if they have not competed successfully for substantial, NIH independent funding from NIH. A "substantial" research award is a research grant award excluding smaller grants that maintain Early Stage Investigator (ESI)/NI status (see full list of awards here: https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm). PD/PIs of NIH Training-Related and Mentored Career Awards are still considered New Investigators if the NIH awards are in any of the following categories: fellowships (F awards), individual or institutional career awards (K awards), and loan repayment contracts (L30, L32, L40, L50, L60). Appointees who have received support from any NIH training grants (T32, T34, T35, T90, D43) are also considered New Investigators.

OR

2. At-Risk Investigator

For the purpose of this NOFO, an investigator is considered an At-Risk Investigator if they have had prior support as a Principal Investigator on a substantial independent research award and, unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year. A "substantial" research award is a research grant award excluding smaller grants that maintain ESI/NI status

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
This Funding Opportunity Announcement does not accept applications proposing clinical trials.

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Components of Participating Organizations:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Human Genome Research Institute (NHGRI)